bioMerieux sees growth restrained by competition:
This article was originally published in Clinica
Executive Summary
With competition heating up, particularly in the $700m global haemostasis market, bioMerieux achieved modest sales growth in 2004. Revenues rose by 1.8% (5.2% excluding currency effects) to E931m ($1.2bn), with the strongest sales growth in Latin America and India and molecular biology. 85% of sales were of reagents. Fourth-quarter revenues totalled E243m, up 1.2% (4.2% at constant exchange rates). Meanwhile, the Marcy l'Etoile, France-based group has exercised an option to develop RNA-based diagnostics under its recent agreement with Gen-Probe.